Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Bladder cancer: unmet need for novel therapies

Petros Grivas, MD, PhD, of the Seattle Cancer Care Alliance, Seattle, WA, discusses the PrE0807 (NCT03532451) trial that investigated the feasibility of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.